Your browser doesn't support javascript.
loading
The 2022 Assisi Think Tank Meeting: White paper on optimising radiation therapy for breast cancer.
Aristei, C; Kaidar-Person, O; Boersma, L; Leonardi, M C; Offersen, B; Franco, P; Arenas, M; Bourgier, C; Pfeffer, R; Kouloulias, V; Bölükbasi, Y; Meattini, I; Coles, C; Luis, A Montero; Masiello, V; Palumbo, I; Morganti, A G; Perrucci, E; Tombolini, V; Krengli, M; Marazzi, F; Trigo, L; Borghesi, S; Ciabattoni, A; Ratosa, I; Valentini, V; Poortmans, P.
Affiliation
  • Aristei C; Radiation Oncology Section, Department of Medicine and Surgery, University of Perugia and Perugia General Hospital, Perugia, Italy. Electronic address: cynthia.aristei@unipg.it.
  • Kaidar-Person O; Breast Radiation Unit, Radiation Oncology, Sheba Medical Center, Ramat Gan, Israel.
  • Boersma L; Radiation Oncology (Maastro), GROW School for Oncology and Developmental Biology, Maastricht University Medical Centre, Maastricht, the Netherlands.
  • Leonardi MC; Division of Radiation Oncology, IEO European Institute of Oncology, IRCCS, Milan, Italy.
  • Offersen B; Department of Experimental Clinical Oncology, Department of Oncology, Danish Centre for Particle Therapy, Aarhus University Hospital, Aarhus, Denmark.
  • Franco P; Depatment of Translational Medicine, University of Eastern Piedmont and Department of Radiation Oncology, 'Maggiore della Carita`' University Hospital, Novara, Italy.
  • Arenas M; Universitat Rovira I Virgili, Radiation Oncology Department, Hospital Universitari Sant Hoan de Reus, IISPV, Spain.
  • Bourgier C; Radiation Oncology, ICM-Val d' Aurelle, Univ Montpellier, Montpellier, France.
  • Pfeffer R; Oncology Institute, Assuta Medical Center, Tel Aviv and Ben Gurion University Medical School, Israel.
  • Kouloulias V; 2nd Department of Radiology, Radiotherapy Unit, Medical School, National and Kapodistrian University of Athens, Greece.
  • Bölükbasi Y; Koc University, Faculty of Medicine, Department of Radiation Oncology, Istanbul, Turkey.
  • Meattini I; Department of Experimental and Clinical Biomedical Sciences "M. Serio", University of Florence & Radiation Oncology Unit - Oncology Department, Azienda Ospedaliero Universitaria Careggi, Florence, Italy.
  • Coles C; Department of Oncology, University of Cambridge, UK.
  • Luis AM; Department of Radiation Oncology, University Hospital HM Sanchinarro, HM Hospitales, Madrid, Spain.
  • Masiello V; Unità Operativa di Radioterapia Oncologica, Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Gemelli IRCSS Roma, Italy.
  • Palumbo I; Radiation Oncology Section, Department of Medicine and Surgery, University of Perugia and Perugia General Hospital, Perugia, Italy.
  • Morganti AG; DIMES, Alma Mater Studiorum Bologna University, Bologna, Italy; Radiation Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Alma Mater Studiorum Bologna University, Bologna, Italy.
  • Perrucci E; Radiation Oncology Section, Perugia General Hospital, Perugia, Italy.
  • Tombolini V; Radiation Oncology, Department of Radiological, Oncological and Pathological Science, University "La Sapienza", Roma, Italy.
  • Krengli M; DISCOG, Università di Padova e Istituto Oncologico Veneto - IRCCS, Italy.
  • Marazzi F; Unità Operativa di Radioterapia Oncologica, Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Gemelli IRCSS Roma, Italy.
  • Trigo L; Service of Brachytherapy, Department of Image and Radioncology, Instituto Português Oncologia Porto Francisco Gentil E.P.E., Portugal.
  • Borghesi S; Radiation Oncology Unit of Arezzo-Valdarno, Azienda USL Toscana Sud Est, Italy.
  • Ciabattoni A; Department of Radiation Oncology, San Filippo Neri Hospital, ASL Rome 1, Rome, Italy.
  • Ratosa I; Division of Radiation Oncology, Institute of Oncology Ljubljana, Ljubljana, Slovenia; Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.
  • Valentini V; Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Università Cattolica del Sacro Cuore e Fondazione Policlinico Gemelli IRCSS Roma, Italy.
  • Poortmans P; University of Antwerp, Faculty of Medicine and Health Sciences, Antwerp, Belgium; Department of Radiation Oncology, Iridium Kankernetwerk, Antwerp, Belgium, Faculty of Medicine and Health Sciences, Antwerp, Belgium.
Crit Rev Oncol Hematol ; 187: 104035, 2023 Jul.
Article in En | MEDLINE | ID: mdl-37244324
The present white paper, referring to the 4th Assisi Think Tank Meeting on breast cancer, reviews state-of-the-art data, on-going studies and research proposals. <70% agreement in an online questionnaire identified the following clinical challenges: 1: Nodal RT in patients who have a) 1-2 positive sentinel nodes without ALND (axillary lymph node dissection); b) cN1 disease transformed into ypN0 by primary systemic therapy and c) 1-3 positive nodes after mastectomy and ALND. 2. The optimal combination of RT and immunotherapy (IT), patient selection, IT-RT timing, and RT optimal dose, fractionation and target volume. Most experts agreed that RT- IT combination does not enhance toxicity. 3: Re-irradiation for local relapse converged on the use of partial breast irradiation after second breast conserving surgery. Hyperthermia aroused support but is not widely available. Further studies are required to finetune best practice, especially given the increasing use of re-irradiation.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Breast Neoplasms Type of study: Guideline Limits: Female / Humans Language: En Journal: Crit Rev Oncol Hematol Journal subject: HEMATOLOGIA / NEOPLASIAS Year: 2023 Document type: Article Country of publication: Netherlands

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Breast Neoplasms Type of study: Guideline Limits: Female / Humans Language: En Journal: Crit Rev Oncol Hematol Journal subject: HEMATOLOGIA / NEOPLASIAS Year: 2023 Document type: Article Country of publication: Netherlands